Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
A new editorial discusses the role of real-word data against a background of increasingly intense discussion on pricing and affordability of new cancer drugs, the responsible behaviour of pharmaceutical companies, and the lack of transparency in pricing and R&D expenditure.
The authors, Wim van Harten and Maarten J IJzerman, from the The Netherlands Cancer Institute, University Twente, European Organization of Cancer Institutes, Rijnstate Hospital, and the Luxembourg Institute of Health, explain that Real-World Evidence (RWE) may play a pivotal role in developing sustainable cancer care, because it allows much better estimates of actual drug use and costs and increases transparency in health outcomes.
Read the full editorial here.
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.